New Two-Drug attack on Tough-to-Treat hodgkin lymphoma

NCT ID NCT03681561

Recruiting now Disease control Sponsor: Veronika Bachanova Source: ClinicalTrials.gov ↗

Summary

This study is testing a combination of two drugs, nivolumab and ruxolitinib, for adults whose Hodgkin lymphoma has returned or not responded to prior treatments. The first part aims to find the safest dose of ruxolitinib to give with nivolumab. The second part will see how well this combination controls the cancer for at least three months.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Indiana Melvin and Bren Simon Comprehensive Cancer Center
WITHDRAWN

Indianapolis, Indiana, 46202, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Illinois Cancer Center
COMPLETED

Chicago, Illinois, 60612, United States
University of Iowa Hospitals and Clinics
ACTIVE_NOT_RECRUITING

Iowa City, Iowa, 52242, United States
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Wisconsin
RECRUITING

Madison, Wisconsin, 53705, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

HODGKIN LYMPHOMA